Few entrepreneurs who appear on ABC's Shark Tank are lucky enough to receive an offer from one of the show’s panel of angel investors, but recently Josh and Sara Margulis had to choose from three proposals. The married entrepreneurs co-founded Honeyfund, an online honeymoon registry, in 2006. Although the company wasn’t brand new when the two appeared on the show in 2014, they wanted the experience and capital to grow their business. Even though people who work on the Shark Tank show actually used Honeyfund and invited the Margulises to apply to be contestants, nothing was certain. 'We had a little bit of a leg up, but when you walk into the shark tank, all bets are off,' Sara said. Ultimately, they decided to work with Kevin O’Leary (a.k.a ‘Mr. Wonderful’), a decision that has served their company well. 'We think he might have been looking for a crowdfunding play, so he jumped on it,' Sara explained. The Margulises encourage aspiring entrepreneurs to get started in growing their business, rather than waiting for their product to be perfect. 'If you’re building something online, I would put it out there before you’re comfortable,' Josh said. 'It’s going to feel painful to put it out there, but it’s better to get it out there and get some feedback.'
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.